APA (7th ed.) Citation

Kato, K., Izutsu, K., Nishikori, M., Shibayama, H., Maeda, Y., Yoshimura, K., . . . Suzumiya, J. (2024). End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse. International Journal of Hematology, 119(6), 677-685. https://doi.org/10.1007/s12185-024-03738-8

Chicago Style (17th ed.) Citation

Kato, Koji, et al. "End-of-treatment 18[F]-FDG PET Can Predict Early Progression in Patients Receiving Bendamustine-rituximab for Follicular Lymphoma in First Relapse." International Journal of Hematology 119, no. 6 (2024): 677-685. https://doi.org/10.1007/s12185-024-03738-8.

MLA (9th ed.) Citation

Kato, Koji, et al. "End-of-treatment 18[F]-FDG PET Can Predict Early Progression in Patients Receiving Bendamustine-rituximab for Follicular Lymphoma in First Relapse." International Journal of Hematology, vol. 119, no. 6, 2024, pp. 677-685, https://doi.org/10.1007/s12185-024-03738-8.